Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...
Spotlighting Innovation in Novel Targeting Formats & Payloads to Enhance Delivery, Overcome Payload Resistance and Expand Therapeutic Reach Novel conjugates have become one of the most competitive and ...
> The FDA has reorganized its oncology division. The Center for Drug Evaluation and Research's Office of Oncology Drug Products has been reorganized and renamed the Office of Hematology and Oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results